• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Fat Tail Daily

Investment Ideas From the Edge of the Bell Curve

  • Menu
    • Commodities
      • Resources and Mining
      • Copper
      • Gold
      • Iron Ore
      • Lithium
      • Silver
      • Graphite
      • Rare Earths
    • Technology
      • AI
      • Bitcoin
      • Cryptocurrency
      • Energy
      • Financial Technology
      • Bio Technology
    • Market Analysis
      • Latest ASX News
      • Dividend Shares
      • ETFs
      • Stocks and Bonds
    • Macro
      • Australian Economy
      • Central Banks
      • World Markets
    • Small Caps
    • More
      • Investment Guides
      • Premium Research
      • Editors
      • About
      • Contact Us
  • Latest
  • Fat Tail Series
  • About Us
Technology Bio Tech

Recce Pharmaceuticals Shares Up on Possible COVID-19 Treatment

Like 0

By Ryan Clarkson-Ledward, Thursday, 09 July 2020

That’s where biotech companies like Recce Pharmaceuticals Ltd [ASX:RCE] come in. A small-cap that is trading 50% higher today after it was selected to see if it could help fight the coronavirus....

We’ve reached a point where it’s almost certain that herd immunity won’t beat the ‘rona.

COVID-19 is showing no signs of slowing down in nations that opted for this strategy. With Sweden one of the prime examples of this outcome.

To date, they have one of the highest mortality rates per capita from the pandemic. Not exactly the kind of recognition you want.

Suffice to say, both Sweden and the rest of the world need a cure.

That’s where biotech companies like Recce Pharmaceuticals Ltd [ASX:RCE] come in. A small-cap that is trading 50% higher today after it was selected to see if it could help fight the coronavirus.

Hunt for a solution

Yesterday afternoon, after the market close, Recce made a big announcement.

The company is set to begin working with the CSIRO and Doherty Institute. Putting their synthetic anti-infectives to the ultimate test: a SARS-CoV-2 (coronavirus) screening program.

In other words, they will take part in a coordinated effort to find a treatment for COVID-19. One of a handful of promising treatments that may help us find a way to beat this deadly virus.

Naturally, it is a huge win and honour for Recce. With their non-executive Chairman Dr John Prendergast commenting:

‘We are very pleased to have been selected by the CSIRO, one of the largest and most diverse scientific research organisations in the world, to investigate the efficacy of two of our promising compounds against SARS-CoV-2.

‘The compounds’ unique, universal mechanisms of action indicate potential to attack a broad range of viruses and as well, overcome the threat of viruses’ typical hyper-mutation into new and deadly pathogens.’

And it is this late point, on mutations, that Recce will be well aware of. Their entire objective to date has been in identifying anti-viral solutions that aren’t vulnerable to antimicrobial resistance. The phenomenon that has limited the viability of so many other drugs both past and present.

For now though, the goal is simply to find any kind of solution. A goal that Recce may play some part in; only time will tell.

A long way to go

As is always the case for any drug, this won’t be a quick affair.

Even with fast-tracked research, the screening process will take time. Ensuring that no stone is left unturned in the pursuit of a workable treatment.

Recce hasn’t even provided a timeline for the next stages, let alone the entire roadmap. All we know is that they will update the market as the screening process progresses. That is, if their two candidates continue to show potential.

It is by no means a guaranteed win, but it certainly provides hope.

And for shareholders, it could be the beginning of some much larger returns.

However, biotech isn’t the only promising sector for small-caps at the moment. There are a range of incredible companies that are looking likely to boom in the coming months. Many of which could offer some amazing returns.

For four of our favourite picks, check out our high-value small caps report, right here.

Because in this market, finding tiny companies with big potential may be the best remedy when it comes to your financial health.

Regards,

Ryan Clarkson-Ledward,
For Money Morning

All advice is general advice and has not taken into account your personal circumstances.

Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

Comments

Subscribe
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments
Ryan Clarkson-Ledward

Ryan’s Premium Subscriptions

Publication logo
Fat Tail Investment Research

Latest Articles

  • A radically innovative industry set to soar
    By Callum Newman

    Pretty soon we’re going to have flying transportation. It could cut car travel demand again. See below for my moonshot idea on this.

  • Debt and declining demographics are a dangerous combination
    By Brian Chu

    Our monetary system plays a big role in causing the demographic decline. How that works is hidden from many. But we can be the remedy by sharing our wisdom with the younger generation.

  • Critical Metal Stocks: Following the Iron Ore Playbook
    By James Cooper

    How does inconceivable capex find its way into new mining projects? Answer: Higher commodity prices. James Cooper compares the iron ore boom from the early 2000s to what may lie ahead for critical minerals.

Primary Sidebar

Latest Articles

  • A radically innovative industry set to soar
  • Debt and declining demographics are a dangerous combination
  • Critical Metal Stocks: Following the Iron Ore Playbook
  • Copper traders: gettin’ jiggy with it
  • Australia ain’t the USA…and that’s great!

Footer

Fat Tail Daily Logo
YouTube
Facebook
x (formally twitter)
LinkedIn

About

Investment ideas from the edge of the bell curve.

Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.

Quick Links

Subscribe

About

FAQ

Terms and Conditions

Financial Services Guide

Privacy Policy

Get in Touch

Contact Us

Email: support@fattail.com.au

Phone: 1300 667 481

All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.

Fat Tail Logo

Fat Tail Daily is brought to you by the team at Fat Tail Investment Research

Copyright © 2025 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988